Telix Schedules April Webinar Showcasing TLX597-Tx OPTIMAL-PSMA2 Trial Data
Telix will host a webinar on April 29 EDT and April 30 AEST exploring its second-generation PSMA-targeted radioligand TLX597-Tx, featuring initial data from the OPTIMAL-PSMA2 investigator trial. The presentation by Prof. Louise Emmett and Dr. David N. Cade will outline Telix’s multi-product prostate cancer therapy strategy.
1. Webinar Schedule and Focus
Telix will host an educational webinar on April 29 at 7:30 p.m. EDT and April 30 at 9:30 a.m. AEST to explore the evolution of PSMA-targeted radionuclide therapy and outline the company’s multi-product development strategy across the prostate cancer continuum.
2. OPTIMAL-PSMA2 Trial Data
Professor Louise Emmett, Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital, will showcase data from the OPTIMAL-PSMA2 investigator-initiated trial evaluating TLX597-Tx (177Lu-DOTA-PSMA), Telix’s novel second-generation small molecule candidate designed to facilitate broader access to lutetium therapy.
3. Expert Speaker Insights
Dr. David N. Cade, Telix Group Chief Medical Officer, will join Prof. Emmett to discuss key factors in developing effective PSMA-targeted therapies, highlighting Telix’s differentiated, multi-product approach and addressing clinical and logistical challenges in radionuclide treatment.
4. Registration and Authorization Status
Participants can register online via the provided link to join the live presentation and Q&A; TLX597-Tx has not received marketing authorization in any jurisdiction and remains in clinical development.